BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Immunophotonics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Immunophotonics\, Inc.'s drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07321847-2292@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:N-dihydrogalactochitosan: Phase 2/3 readout est. (NCT07321847)
DESCRIPTION:N-dihydrogalactochitosan\, phase 2/3\, Colorectal Cancer.\nStud
 y: Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients W
 ith Colorectal Liver Metastases\nEstimated primary completion: December 20
 33. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/n-dihydrogalactoc
 hitosan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07321847
URL:https://assetmemo.bio/drug/n-dihydrogalactochitosan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
